2023 ASCO中国学者口头报告来了！18项研究入围
作者：唐颖 来源：医学论坛网 日期：2023-05-12
导读
一年一度的美国临床肿瘤学会（ASCO）将于北京时间6月3日-6月7日举行。随着中国临床肿瘤研究水平的发展，越来越多中国研究者的研究登上国际舞台。 医学论坛网特整理了口头报告中的中国讲者报告主题。话不多说，让我们看看2023 ASCO年会有哪些值得关注的中国之声呢？（以下排名不分先后，如有遗漏敬请谅解，欢迎留言补充） 01
一年一度的美国临床肿瘤学会（ASCO）将于北京时间6月3日-6月7日举行。随着中国临床肿瘤研究水平的发展，越来越多中国研究者的研究登上国际舞台。
医学论坛网特整理了口头报告中的中国讲者报告主题。话不多说，让我们看看2023 ASCO年会有哪些值得关注的“中国之声”呢？（以下排名不分先后，如有遗漏敬请谅解，欢迎留言补充）
Oral Abstract Session - Hall D2
标题：BL-B01D1，一种EGFR/HER3双特异性ADC治疗局部晚期或转移性实体瘤：首次人类1期研究
原标题：BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study.
Oral Abstract Session - Hall D2
标题：KL590586，下一代选择性RET抑制剂，用于治疗RET融合实体瘤
原标题：A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors.
Oral Abstract Session - Hall B1
标题：术前特瑞普利单抗+含铂双药化疗对比化疗治疗可切除的II/III期非小细胞肺癌：III NEOTORCH研究无事件生存期（EFS）
原标题：Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study.
Oral Abstract Session - Hall D1
标题：AZD3759对比吉非替尼或厄洛替尼治疗EGFR突变阳性的非小细胞肺癌脑转移患者的III期临床研究
原标题：Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis.
Oral Abstract Session - Hall D1
标题：舒沃替尼治疗EGFR 外显子20插入突变非小细胞肺癌：首个研究关键结果
原标题：Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results.
Oral Abstract Session - Hall D1
标题：CHOICE-01研究的最终总生存数据和生物标志物分析：一项探索特瑞普利单抗+化疗对比安慰剂+化疗治疗无EGFR/ALK突变的晚期非小细胞肺癌的双盲随机III期临床研究
原标题：Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations.
Oral Abstract Session - Arie Crown Theater
标题：术前PD-1单抗特瑞普利单抗+SOX/XELOX化疗对比单纯SOX/XELOX治疗局部晚期胃癌及胃食管结合部肿瘤：一项前瞻性、随机、开放标签II期临床研究结果
原标题：Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial.
Oral Abstract Session - S100a
标题：用于胃癌监测的常见血液检测的AI血液特征：一个19万人队列分析
香港科技大学 Tsz Chun Bryan Wong
原标题：AI blood signature in common blood tests for detection of gastric cancer in a cohort of 190,000 individuals.
Oral Abstract Session-Hall D2
标题：新辅助mFOLFOX6±放疗对比氟尿嘧啶+放疗治疗局部晚期直肠癌的长期结局：一项多中心、随机III期试验
原标题：Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial.
Oral Abstract Session - Hall B1
标题：同步放化疗后辅助顺铂+吉西他滨对比顺铂+5-氟尿嘧啶治疗N2-3期鼻咽癌：一项多中心、开放标签、随机、控制变量III期临床研究
原标题：Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial.
Oral Abstract Session - Hall B1
标题：诱导化疗+放疗对比顺铂同步放化疗治疗局部进展晚期鼻咽癌：一项开放标签、非劣效性III期随机研究
原标题：Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial.
Oral Abstract Session - Hall B1
标题：PD-1抑制剂信迪利单抗+诱导化疗和同步放化疗（IC-CCRT）对比IC-CCRT治疗局部进展晚期鼻咽癌：一项多中心、III期、随机控制变量研究
原标题：PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM).
Oral Abstract Session - Hall D1
标题：卡瑞利珠单抗+阿帕替尼治疗既往治疗失败或至少经过一线治疗的晚期/复发子宫内膜癌：一项单臂II期临床试验
原标题：Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial.
Oral Abstract Session - Hall D1
标题：替莫唑胺+顺铂vs特瑞普利单抗辅助治疗可切除黏膜黑色素瘤
原标题：Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma.
Clinical Science Symposium S404
原标题：The clinical value of tumor-informed minimal residual disease detection in sarcoma.
Oral Abstract Session - S100a
标题：Golidocitinib治疗复发/难治外周T细胞淋巴瘤：多国关键结果的初步分析（JACKPOT8）
原标题：Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8).
Oral Abstract Session - Hall D2
标题：BCMA/CD19双靶向快速CAR-T GC012F治疗复发/难治多发性骨髓瘤的I期临床研究结果更新
原标题：Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM).
专场：Oral Abstract Session - Arie Crown Theater
标题：PD-L1/TGF-βRII双抗SHR-1701联合EZH2抑制剂SHR2554治疗经治的晚期淋巴瘤和实体瘤患者I期研究
原标题：Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors.
评论
我要跟帖
